RecruitingNCT02440763

The EUROSCA Natural History Study

Sponsor

Ataxia Study Group

Enrollment

400 participants

Start Date

Jul 1, 2005

Study Type

OBSERVATIONAL

Conditions

Spinocerebellar ataxia

Summary

The key goals of EUROSCA-NHS is to determine and compare the rate of disease progression in SCA1, SCA2, SCA3 and SCA6 including determination of the order and occurrence of non-ataxia symptoms, assessment of activities of daily living (ADL) and quality of life (QoL), and identification of predictors of disease progression and survival.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Progressive, otherwise unexplained ataxia
Positive genetic testing for SCA1, SCA2, SCA3, and SCA6
Written informed consent by the patient or his legal agent

Exclusion Criteria1

None.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(16)

Department of Neurology, Medical University, Innsbruck

Innsbruck, Austria

Université Libre de Bruxelles (ULB), Neurology Service - ULB Hôpital Erasme, ULB Laboratory of Experimental Neurology

Brussels, Belgium

Hôpital de la Pitié-Salpêtrière, Département de Génétique

Paris, France

Department of Neurology, St. Josef Hospital, University Hospital of Bochum

Bochum, Germany

Department of Neurology, University of Bonn

Bonn, Germany

Department of Neurology, University Clinic Essen, University of Duisburg-Essen

Essen, Germany

Department of Neurology, University of Frankfurt

Frankfurt, Germany

Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tübingen

Tübingen, Germany

Department of Medical Genetics, University of Pecs

Pécs, Hungary

Department of Neurology, Zala County Hospital

Zalaegerszeg, Hungary

Fondazione-IRCCS Istituto Neurologico Carlo Besta

Milan, Italy

Department of Neuroscience, Federico II University Naples

Naples, Italy

Radboud University Medical Center, Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour

Nijmegen, Netherlands

Institute of Psychiatry and Neurology

Warsaw, Poland

University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria

Santander, Spain

Institute of Neurology

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02440763

Related Trials

Natural History of Spinocerebellar Ataxia Type 7 (SCA7)

NCT027414401 location

Ophthalmological Disorders in Dominant Spinal-cerebellar Ataxias

NCT070195581 location

Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients

NCT066330031 location

Hong Kong Spinocerebellar Ataxias Registry

NCT033360081 location

SpeechATAX: Intensive home based biofeedback driven speech treatment for hereditary ataxia

ACTRN126180005192576 locations